Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Mitotane-Driven Apoptosis in Adrenocortical Carcinoma: A Molecular Insight

Armagan Akkus,Muge Gulcihan ONAL.




Abstract

Objective: This study aimed to investigate the responses of antiapoptotic BCL-2 and proapoptotic BID genes to Mitotane and other chemotherapy drugs in Adrenocortical Carcinoma (ACC) cells. The objective was to understand the impact of these drugs on apoptosis-related genes in ACC, shedding light on potential treatment pathways.
Materials and Methods: The study involved the use of ACC cells to assess gene expressions in response to Mitotane, Etoposide, and Cisplatin treatment. Gene expression levels of BCL-2 and BID were measured after drug exposure, providing insights into the modulation of apoptosis pathways by Rt-qPCR.
Results: The results demonstrated that Mitotane notably affected the expression of the proapoptotic BID gene in ACC cells, promoting apoptosis. In contrast, Etoposide and Cisplatin exhibited less consistent effects, with Cisplatin increasing the antiapoptotic BCL-2 gene and decreasing the proapoptotic BID gene compared to Mitotane.
Conclusion: This study revealed that Mitotane, as well as other chemotherapy drugs, influences the expression of key apoptosis-related genes in ACC cells. Mitotane showed a significant effect on the proapoptotic BID gene, indicating its potential as a treatment option for ACC. The findings suggest that Mitotane impacts ACC cells through multiple apoptosis pathways, highlighting its significance in ACC therapy.

Key words: ACC, Apoptosis, Bid gene, Bcl-2 gene, Mitotane.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.